title: [New targets and new drugs in thoracic oncology].
abstract: A number of mechanisms that drive oncogenesis have been deciphered over the last 20 years. The main oncogenic factors in the field of thoracic oncology are mutations of EGFR, KRAS, and EML4-ALK translocation, which are most often reported in adenocarcinomas. However, new molecular targets have been highlighted recently including BRAF mutations, HER2 or PI3K, new translocations such as ROS1 or KIF5B-RET. Molecular abnormalities have also been identified in tumors other than adenocarcinoma (squamous and small cell carcinoma). Therapeutic strategies have been designed to inhibit these signaling pathways including monoclonal antibodies and tyrosine kinase inhibitors. Some of these molecules are now approved as therapies, others are currently undergoing testing in clinical trials. We here present a review of novel targeted agents for lung cancer.
authors.affiliation: Service de pneumologie, hôpital Larrey, CHU de Toulouse, université Paul-Sabatier, 31000 Toulouse, France.
authors.forename: D
authors.initials: D
authors.lastname: Rouviere
authors.affiliation: Service de pneumologie, hôpital Larrey, CHU de Toulouse, université Paul-Sabatier, 31000 Toulouse, France.
authors.forename: E
authors.initials: E
authors.lastname: Bousquet
authors.affiliation: Service de pneumologie, hôpital Larrey, CHU de Toulouse, université Paul-Sabatier, 31000 Toulouse, France; Service d'oncologie médicale, institut Claudius-Regaud, 31000 Toulouse, France.
authors.forename: E
authors.initials: E
authors.lastname: Pons
authors.affiliation: Service de pneumologie, hôpital Larrey, CHU de Toulouse, université Paul-Sabatier, 31000 Toulouse, France.
authors.forename: J-D
authors.initials: JD
authors.lastname: Milia
authors.affiliation: Service de pneumologie, hôpital Larrey, CHU de Toulouse, université Paul-Sabatier, 31000 Toulouse, France.
authors.forename: N
authors.initials: N
authors.lastname: Guibert
authors.affiliation: Service de pneumologie, hôpital Larrey, CHU de Toulouse, université Paul-Sabatier, 31000 Toulouse, France. Electronic address: mazieres.j@chu-toulouse.fr.
authors.forename: J
authors.initials: J
authors.lastname: Mazieres
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use*; D018734:Genes, erbB-2; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D058990:Molecular Targeted Therapy; D009154:Mutation; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D015514:Oncogene Proteins, Fusion / Q000037:antagonists & inhibitors / Q000235:genetics; D009857:Oncogenes; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D015507:Drugs, Investigational; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases; D011518:Proto-Oncogene Proteins; D048493:Proto-Oncogene Proteins B-raf; D018719:Erb-b2 Receptor Tyrosine Kinases; C573239:KIF5B-RET fusion protein, human; C508053:ERBB2 protein, human; C062333:ROS1 protein, human; C482119:BRAF protein, human
keywords: Biomarkers; Biomarqueurs; Cancer bronchique; Lung cancer; Targeted therapy; Thérapies ciblées